 |
| |
|
±¤¸í¼¼ÇÁÇǶó¹Ìµå³ªÆ®·ýÁÖ»ç500mg
|
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ(52)
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A29552261]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1º´(2007.01.01)(ÇöÀç¾à°¡)
\6,277 ¿ø/1º´(2003.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¡Û À¯È¿±ÕÁ¾
Æ÷µµ±¸±Õ, ¿¬¼â±¸±Õ(Àå³»±¸±Õ Á¦¿Ü), ÆéÅ䱸±Õ, ÆéÅ俬¼â±¸±Õ, ´ëÀå±Õ, ½ÃÆ®·Î¹ÚÅÍ, Ŭ·¹ºê½Ã¿¤¶ó, ¿£Å׷ιÚÅÍ, ÇÁ·ÎÅ׿콺, ½´µµ¸ð³ª½º, ÀÎÇ÷翣ÀÚ±Õ, ¾Æ½Ã³×Åä¹ÚÅÍ, ¹ÚÅ×·ÎÀ̵å
¡Û ÀûÀÀÁõ
- ÆÐÇ÷Áõ, ¼ö¸·¿°
- È»ó, ¼ö¼úâ µîÀÇ 2Â÷°¨¿°
- ÀÎÈĵο°(ÀÎÈijó¾ç), Æíµµ¿°(ÆíµµÁÖÀ§¿°, ÆíµµÁÖÀ§³ó¾ç), ¾Ç¿°, ¾Ç°ñÁÖº¯ÀÇ ¿¬Á¶Á÷¿°
- ±Þ¤ý¸¸¼º ±â°üÁö¿°, ±â°üÁöÈ®ÀåÁõ(°¨¿° ½Ã), ¸¸¼ºÈ£Èí±â ÁúȯÀÇ 2Â÷°¨¿°, Æó·Å, Æó³ó¾ç, ³óÈä
- ½Å¿ì½Å¿°, ¹æ±¤¿°, Àü¸³¼±¿°, ºÎ°íȯ¿°
- ´ã³¶¿°, ´ã°ü¿°
- º¹¸·¿°(°ñ¹Ýº¹¸·¿°, ´õ±Û¶ó½º¿Í³ó¾ç Æ÷ÇÔ), Àڱúμӱ⿰, Àڱó»°¨¿°, ÀÚ±ÃÁÖÀ§Á¶Á÷¿°, ¹ÙÅ丰¼±¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û ¼ºÀÎ : ¼¼ÇÁÇǶó¹Ìµå·Î¼ 1ÀÏ 1¢¦2g(¿ª°¡)À» 2ȸ ºÐÇÒ Á¤¸Æ ¶Ç´Â Á¡Àû Á¤¸ÆÁÖ»çÇÑ´Ù.
¡Û ¼Ò¾Æ : 1ÀÏ Ã¼Áß Kg´ç 30¢¦80mg(¿ª°¡)À» 2¢¦3ȸ ºÐÇÒ Á¤¸Æ ¶Ç´Â Á¡Àû Á¤¸ÆÁÖ»çÇÑ´Ù.
¡Û ³Ä¡¼º ¶Ç´Â ÁßÁõ°¨¿°Áõ : Áõ»ó¿¡ µû¶ó 1ÀÏ ¼ºÀÎ 4g(¿ª°¡), ¼Ò¾Æ´Â üÁß Kg´ç 150mg(¿ª°¡)±îÁö Áõ·®ÇÏ¿© 2¢¦3ȸ ºÐÇÒ ÁÖ»çÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù
<ÀÌ ¾àÀÇ Á¶Á¦¹ý>
Á¤¸ÆÁÖ»ç ½Ã´Â ÁÖ»ç¿ë¼ö, »ý¸®½Ä¿°ÁÖ»ç¾× ¶Ç´Â 5% Æ÷µµ´ç ÁÖ»ç¾×¿¡ ³ì¿© õõÈ÷ ÁÖ»çÇÑ´Ù. ¶ÇÇÑ Á¡Àû Á¤¸ÆÁÖ»ç ½Ã´Â ´ç¾×, ÀüÇØÁú¾×, ¾Æ¹Ì³ë»êÁ¦Á¦ µîÀÇ º¸¾×¿¡ ³ì¿© 30¢¦60ºÐ¿¡ °ÉÃÄ ÁÖ»çÇϵÇ, ³ìÀÏ ¶§ ÁÖ»ç¿ë¼ö´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù(ÁÖ»ç¿ë¼ö¸¦ »ç¿ëÇÏ¸é ¿ë¾×ÀÌ µîÀåÀÌ µÇÁö ¾ÊÀ¸¹Ç·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù.).
|
| ±Ý±â |
ÀÌ ¾à¿¡ ÀÇÇÏ¿© ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ |
| ½ÅÁßÅõ¿© |
1) ÀÌ ¾à ¶Ç´Â ¼¼Æè°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀ» ¿øÄ¢À¸·Î Çϳª ºÎµæÀÌ Åõ¿©ÇÒ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
2) Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
3) º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±âÁõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀΠȯÀÚ
4) ÁßÁõÀÇ °£, ½ÅÀå¾Ö ȯÀÚ(Ç÷Áß³óµµ°¡ Áö¼ÓµÇ¹Ç·Î Åõ¿©·®À» °¨¼ÒÇϰųª Åõ¿©°£°ÝÀ» µÎ°í »ç¿ëÇÑ´Ù.)
5) °æ±¸¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ ¶Ç´Â ºñ°æ±¸¿µ¾ç ȯÀÚ, °í·ÉÀÚ, Àü½Å»óŰ¡ ³ª»Û ȯÀÚ(ºñŸ¹Î K °áÇÌÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÑ´Ù.) |
| ÀÌ»ó¹ÝÀÀ |
1) ¼ï : µå¹°°Ô ¼ïÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÏ°í ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, ¾îÁö·¯¿ò, º¯ÀÇ, À̸í, ¹ßÇÑ µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
2) °ú¹Î¹ÝÀÀ : ¹ßÁø, µÎµå·¯±â, È«¹Ý, °¡·Á¿ò, ¹ß¿, °üÀýÅë µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) ¼Òȱâ°è : µå¹°°Ô ¹ß¿, º¹Åë, ¹éÇ÷±¸ Áõ°¡, Á¡¾×, Ç÷¾×º¯À» ¼ö¹ÝÇÏ´Â ÁßÁõÀÇ ¼³»ç¸¦ ÁÖ Áõ»óÀ¸·Î ÇÏ´Â ÁßÁõÀÇ ´ëÀå¿°À¸·Î ³»½Ã°æ °Ë»ç¿¡ ÀÇÇØ À§¸·¹Ý µîÀÇ Çü¼ºÀ» º¼ ¼ö ÀÖ´Â À§¸·¼º´ëÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. º¹Åë, ºó¹øÇÑ ¼³»ç°¡ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Áï½Ã Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù. ¶ÇÇÑ ¶§¶§·Î ¼³»ç, ±¸¿ª, ±¸Åä µå¹°°Ô ½Ä¿åºÎÁø µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì°¡ ÀÖ´Ù.
4) È£Èí±â°è : µå¹°°Ô ¹ß¿, ±âħ, È£Èí°ï¶õ, ÈäºÎ X¼± ÀÌ»ó, È£»ê±¸ Áõ°¡ µîÀ» ¼ö¹ÝÇÏ´Â °£Áú¼º Æó·Å, È£»ê±¸¼º ÆóħÀ± µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÄÚ¸£Æ¼ÄÚÀ̵å Åõ¿© µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
5) Ç÷¾×°è : ¶§¶§·Î °ú¸³±¸ °¨¼Ò, ÀûÇ÷±¸ °¨¼Ò, È£»ê±¸ Áõ°¡, Ç÷¼ÒÆÇ °¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ ´Ù¸¥ ¼¼Æè°è Ç×»ý¹°Áú Åõ¿© ½Ã ¿ëÇ÷¼º ºóÇ÷ÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù.
6) ÇǺΠ: ´Ù¸¥ ¼¼Æè°è Ç×»ý ¹°Áú Åõ¿© ½Ã ½ºÆ¼ºì½º-Á¸½¼ÁõÈıº, µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ°¡ ÀϾ ¼ö°¡ ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ÀÖÀ» °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
7) °£Àå : ¶§¶§·Î AST, ALT, ALP, LDH, ºô¸®·çºó, ¥ã-GTPÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ½ÅÀå : µå¹°°Ô ±Þ¼º ½ÅºÎÀü µîÀÇ ÁßÁõÀÇ ½ÅÀå¾Ö ¶§¶§·Î BUN »ó½Â, Ç÷ÁßÅ©·¹¾ÆÆ¼´Ñ »ó½Â, ÇÌ´¢, Ç÷´¢, ´Ü¹é´¢ µîÀÇ ½ÅÀå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î °Ë»ç¸¦ ½Ç½ÃÇÏ´Â µî ÃæºÐÈ÷ °üÂûÇÏ¿© ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
9) ±Õ±³´ëÁõ : µå¹°°Ô ±¸³»¿°, ĵð´ÙÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
10) ºñŸ¹Î°áÇÌÁõ : µå¹°°Ô ºñŸ¹Î K °áÇÌÁõ»ó(ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ, ÃâÇ÷°æÇâ µî), ºñŸ¹Î B±º °áÇÌÁõ»ó(¼³¿°, ±¸³»¿°, ½Ä¿åºÎÁø, ½Å°æ¿° µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
11) ±âŸ : µå¹°°Ô µÎÅë, ¿°¨, Àü½Å±Çۨ ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ¾ËÄڿðú º¹¿ë ½Ã µð¼³ÇǶ÷ À¯»çÈ¿°ú(È«Á¶, ±¸¿ª, ½É°èÇ×Áø, ´ÙÇÑ, µÎÅë µîÀÇ Áõ»ó)°¡ ³ªÅ¸³¯ ¼ö°¡ ÀÖ´Ù.
2) À¯»çÈÇÕ¹°(´Ù¸¥ ¼¼Æè°è Ç×»ý¹°Áú)°ú Ǫ·Î¼¼¹Ìµå µîÀÇ ÀÌ´¢Á¦¿Í º´¿ëÅõ¿© ½Ã ½ÅÀå¾Ö°¡ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Cefpiramide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The bactericidal activity of cefpiramide results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
|
| Pharmacology |
Cefpiramide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Cefpiramide is a cephalosporin active against Pseudomonas aeruginosa. It has a broad spectrum of antibacterial activity. Cefpiramide works by inhibiting bacterial cell wall biosynthesis. The plasma half-lives of cefpiramide in rabbits, dogs, and rhesus monkeys were much longer than those of cefoperazone and cefazolin.
|
| Half-life |
Cefpiramide¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 4.44 hours
|
| Absorption |
Cefpiramide¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed following intramuscular injection.
|
| Pharmacokinetics |
Cefpiramide SodiumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ´Ü¹é°áÇÕ : ¸Å¿ì ³ô´Ù.
- ¹Ý°¨±â : ¾à 4.5 ½Ã°£
- ¼Ò½Ç : ÁÖ·Î ´ãÁóÀ¸·Î ¹è¼³µÇ¸ç, ¾à 23%°¡ 24½Ã°£ À̳»¿¡ ´¢¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
|
| Biotransformation |
Cefpiramide¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Cefpiramide¿¡ ´ëÇÑ Toxicity Á¤º¸ Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
|
| Drug Interactions |
Cefpiramide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Cefpiramide¿¡ ´ëÇÑ Description Á¤º¸ Cefpiramide is a third-generation cephalosporin antibiotic.
|
| Dosage Form |
Cefpiramide¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Not Available
|
| Drug Category |
Cefpiramide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial Agents
|
| Smiles String Canonical |
Cefpiramide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1N=NN=C1SCC1=C(N2C(SC1)C(NC(=O)C(NC(=O)C1=CNC(C)=CC1=O)C1=CC=C(O)C=C1)C2=O)C(O)=O
|
| Smiles String Isomeric |
Cefpiramide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](NC(=O)C1=CNC(C)=CC1=O)C1=CC=C(O)C=C1)C2=O)C(O)=O
|
| InChI Identifier |
Cefpiramide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18?,23-/m1/s1/f/h26-28,39H
|
| Chemical IUPAC Name |
Cefpiramide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6R)-7-[[(2R)-2-(4-hydroxyphenyl)-2-[(6-methyl-4-oxo1H-pyridine-3-carbonyl)amino]acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-10-12
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|